Loading company…
Novabiotx develops multimodal Treg cell therapies for several disease areas.
Novabiotx researches and develops multimodal Treg cell therapies for neurodegenerative, autoimmune, and metabolic diseases. Founded in 2022, the company is based in Shanghai, China. In October 2024, it closed a pre-Series A funding round to advance clinical trials for its NP001 project and develop other therapies.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in